depression is a potentially lifethreatening disorder affecting millions of people across the globeit is a huge burden to both the individual and society costing over 9 billion in 2000 alone the world health organisation who cited it as the third leading cause of global disability in 2004 first in the developed world and project it will be the leading cause by 2030the serendipitous discovery of antidepressants has revolutionized both our understanding and management of depression however their efficacy in the treatment of depression has long been debated and recently been brought very much into the public limelight by a controversial publication by kirsch in which the role of placebo response in antidepressant efficacy trials is highlightedwhilst antidepressants offer benefits in both the short and long term important problems persist such as intolerability delayed therapeutic onset limited efficacy in milder depression and the existence of treatmentresistant depression